2cureX continues its IP expansion by securing a patent on its IndiTreat test in Australia
January 6, 2020
2cureX is currently preparing for the launch of IndiTreat in 2020. During this Pre-launch phase it is very important for customers/partners that the technology is clinically validated and protected by a strong patent portfolio. A geographically broad protections further opens new commercial opportunities.
IndiTreat® provides a novel functional test that supports the existing diagnostic processes for clinicians to individualize cancer treatment. The technology identifies the drug treatment to which the individual patient is sensitive and as important to which the patient is resistant.
“It is a pleasure to see that IndiTreat, during 2cureX’s pre-launch activities, is well received by cancer centers, oncologists and patient organizations. There is a clear interest to add a functional test like IndiTreat to the oncologist’s toolbox”, says Ole Thastrup, Chief Executive Officer and he continues; “A prerequisite for a successful launch of IndiTreat is that 2cureX and its clinical partners have shown clinical relevance of the test; but on top of that it is a clear strength to our IndiTreat offering that the test is well protected in major markets.
Maarten van der Linden, Chief Business Officer supplements by saying; “In our discussions with commercial stakeholders and potential partners, the freedom to operate and broad patent protection is essential for the commercial outlook of 2cureX”
For more information about 2cureX:
Ole Thastrup, Chief Executive Officer
Telephone: +45 2211 5399
Svensk Kapitalmarknadsgranskning AB
Phone: +46 11 32 30 732
This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on January 6th, 2020.
2cureX has developed the IndiTreat® (Individual Treatment Design) test. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour and identifies the approved cancer treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient will be provided the selected treatment.
IndiTreat® is being clinically validated in eight clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.
IndiTreat® is presently being introduced into the European market through an Early Access Program.
IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).